Weight Loss
All Treatments
Resources
All Treatments
Weight Loss Treatments
Tirzepatide
Semaglutide
Wegovy Pill
Resources
Healthi App
Blog
Member Meetings
Recipes
Podcast
Patient Sign in
If you have been reading about new weight-loss pills and stronger next-generation shots, the practical question is short. What can actually be prescribed today, what is under FDA review, and what is still being studied and not approved yet.
Three weight-management developments reached FDA approval in the current cycle. One combination medicine is under FDA review. One triple-hormone medicine is producing large trial numbers but is not approved yet, and future approval is not guaranteed.
2026 status snapshot
What is available now—and what is not
Approval, timing, and availability can change. This is the current status of the five developments covered below.
Wegovy tabletsOral semaglutide
Approved now
FoundayoOral GLP-1 medicine
Approved now
Wegovy HDHigher-dose semaglutide injection
Approved now
CagriSemaGLP-1 + amylin combination
Under FDA review
RetatrutideTriple-hormone medicine being studied
Not FDA approved
Semaglutide is now available as an FDA-approved oral tablet for adults with obesity, or adults with overweight and at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity. The maintenance dose is 25 mg once daily, taken in the morning on an empty stomach with up to four ounces of water, followed by at least a 30-minute wait before any food, drink, or other oral medication.
In FDA Study 7, 307 adults with obesity, or with overweight and at least one weight-related condition and without type 2 diabetes, were randomized to Wegovy tablets or placebo alongside diet and activity changes. At Week 64, the estimated mean body-weight change was -13.6% with Wegovy tablets and -2.4% with placebo. That is a group average, not a forecast for any one person.
An oral form is not a milder form of the medicine. Wegovy tablets carry a boxed warning about thyroid C-cell tumors, along with warnings covering pancreatitis, gallbladder disease, hypoglycemia when combined with certain diabetes medicines, kidney injury related to dehydration, serious gastrointestinal reactions, hypersensitivity, diabetic retinopathy complications, increased heart rate, suicidal behavior and ideation, aspiration during anesthesia or deep sedation, and pregnancy-related risk. The dosing rules and the safety profile require individual medical evaluation.
Foundayo is an FDA-approved once-daily oral GLP-1 receptor agonist, meaning a medicine that switches on the GLP-1 receptor in the body. It is indicated for long-term weight reduction in adults with obesity, or adults with overweight and at least one weight-related condition, used with a reduced-calorie diet and physical activity. It can be taken with or without food. The maximum labeled dose is 17.2 mg once daily after gradual dose escalation.
Two 72-week randomized, double-blind, placebo-controlled trials showed statistically significant body-weight reduction versus placebo at Week 72 across all studied dose groups. Those are group averages, not individual forecasts.
Foundayo carries a boxed warning about thyroid C-cell tumors, along with warnings covering pancreatitis, severe gastrointestinal reactions, kidney injury related to dehydration, hypoglycemia with certain diabetes medicines, hypersensitivity, diabetic retinopathy complications, gallbladder disease, aspiration during anesthesia or deep sedation, pregnancy-related risk, and interactions with certain medicines. Any decision to start requires individual medical review.
On March 19, 2026 the FDA approved Wegovy HD, a 7.2 mg higher-dose semaglutide injection, for long-term weight reduction in qualifying adults. A higher dose is not automatically more appropriate for any specific person. Whether it fits depends on health history, tolerability, and licensed medical judgment.
Taken together, the 2026 approved menu now includes daily oral options alongside weekly injections at multiple doses. Choosing among them, escalating carefully, and monitoring for side effects still requires medical review.
CagriSema is a once-weekly fixed-dose combination of cagrilintide and semaglutide. Cagrilintide activates amylin receptors, and amylin is a hormone involved in feeling full after eating and slowing how quickly the stomach empties. Semaglutide is a GLP-1 receptor agonist. Novo Nordisk submitted CagriSema to the US FDA for weight management in December 2025, and it remains under review, not approved yet. Future approval is not guaranteed and the timing is not known.
The peer-reviewed REDEFINE 1 trial studied the two ingredients coadministered in adults with obesity or overweight and reported greater average weight reduction than placebo and than either component alone. That is a group average, not an individual prediction. CagriSema is not commercially available and is not offered by HealthiCare.
Mechanism map
How the pathways differ
The next generation is not simply a higher dose. Researchers are combining or targeting additional hormone pathways.
Semaglutide
GLP-1
GLP-1 pathway
CagriSema
GLP-1+Amylin
Under FDA review
Retatrutide
GLP-1+GIP+Glucagon
Not FDA approved
Retatrutide is being studied but is not approved yet, and future approval is not guaranteed. It targets three hormone pathways at once, GIP, GLP-1, and glucagon. These pathways are involved in appetite, blood-sugar regulation, food intake, and how the body uses or expends energy. Lilly's mechanism summary says early evidence suggests retatrutide may reduce food intake, help maintain energy expenditure during weight loss, and affect glucose and fat metabolism. That is an explanation of what researchers are trying to affect, not proof of what any individual would experience.
In May 2026, Lilly announced summary results from its late-stage TRIUMPH-1 trial of retatrutide. At 80 weeks, the company reported an average 28.3% weight reduction for participants assigned to 12 mg, compared with 2.1% for placebo. Those are group results announced by Lilly. They have not been compared head-to-head against marketed medicines in that release, and they do not forecast an individual result. Retatrutide cannot legally be prescribed by HealthiCare or any other telehealth provider as a finished weight-loss product.
The FDA has stated that retatrutide and cagrilintide are not components of any FDA-approved medicine and have not been found safe and effective for any condition. The agency has warned businesses marketing unapproved retatrutide directly to consumers. If a website is selling retatrutide, cagrilintide, or CagriSema for weight loss right now, that is a reason to be cautious. A positive trial gives regulators something to review. It does not authorize a prescription or a sale.
CagriSema may or may not clear FDA review, retatrutide may or may not follow, and no one can promise a timeline, a price, or insurance coverage in advance. Waiting on a specific future medicine means waiting on conditions no one can currently confirm, while your health history, current medicines, tolerability, and goals can be reviewed now within care that already exists.
That is where HealthiCare's current programs fit. Personalized Semaglutide is $174 billed monthly, or $443.70 every three months, which works out to a $147.90 monthly equivalent and a 15% saving on the quarterly plan. Personalized Tirzepatide is $264 billed monthly, or $673.20 every three months, a $224.40 monthly equivalent with the same 15% quarterly saving.
The medication price does not change as your prescribed dose changes. Clinical and coach support are part of the program, there is no separate membership fee, there are no contracts, and you can cancel whenever you choose. Both are FSA/HSA eligible, and timing may vary.
These are HealthiCare's own programs and are distinct from Wegovy, Ozempic, Mounjaro, Zepbound, Foundayo, Wegovy HD, CagriSema, and retatrutide, so nothing above about those medicines transfers here. For broader context on GLP-1 costs, see our guide on whether GLP-1 treatment is worth the investment.
A personal decision starts here
Find out whether treatment may be appropriate for you
You share your health history and goals. A licensed clinician reviews what you write and determines whether a prescription is appropriate. Completing the assessment does not guarantee a prescription. If one is written, a partner pharmacy prepares and ships the medication.
Begin the private online assessment
This article is for informational purposes and does not replace individualized medical advice. A licensed clinician should evaluate your health history and current medicines before any weight-management medication is started.
August 20, 2026
